Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
Ray KK, Ditmarsch M, Kallend D, Niesor EJ, Suchankova G, Upmanyu R, Anzures-Cabrera J, Lehnert V, Pauly-Evers M, Holme I, Štásek J, van Hessen MW, Jones P; dal-ACUTE Investigators. Ray KK, et al. Among authors: pauly evers m. Eur Heart J. 2014 Jul 14;35(27):1792-800. doi: 10.1093/eurheartj/ehu105. Epub 2014 Mar 17. Eur Heart J. 2014. PMID: 24639426 Clinical Trial.
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).
Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, Pauly-Evers M, Nikolcheva T, Czech C, Borroni E, Ricci B, Dukart J, Mannino M, Carey T, Moran E, Gilaberte I, Muelhardt NM, Gerlach I, Santarelli L, Ostrowitzki S, Fontoura P. Nave S, et al. Among authors: pauly evers m. J Alzheimers Dis. 2017;58(4):1217-1228. doi: 10.3233/JAD-161309. J Alzheimers Dis. 2017. PMID: 28550255 Free PMC article. Clinical Trial.
Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice.
Nordquist RE, Savignac H, Pauly-Evers M, Walker G, Knoflach F, Borroni E, Glaentzlin P, Bohrmann B, Messer J, Ozmen L, Albientz A, Spooren W. Nordquist RE, et al. Among authors: pauly evers m. Behav Pharmacol. 2008 Sep;19(5-6):518-29. doi: 10.1097/FBP.0b013e32830cd7f5. Behav Pharmacol. 2008. PMID: 18690106
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, Hershberger VS, Pauly-Evers M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Osborne A, Weikert R, Fauser S. Sahni J, et al. Among authors: pauly evers m. Ophthalmology. 2019 Aug;126(8):1155-1170. doi: 10.1016/j.ophtha.2019.03.023. Epub 2019 Mar 21. Ophthalmology. 2019. PMID: 30905643 Free article. Clinical Trial.
Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site.
Kew JN, Koester A, Moreau JL, Jenck F, Ouagazzal AM, Mutel V, Richards JG, Trube G, Fischer G, Montkowski A, Hundt W, Reinscheid RK, Pauly-Evers M, Kemp JA, Bluethmann H. Kew JN, et al. J Neurosci. 2000 Jun 1;20(11):4037-49. doi: 10.1523/JNEUROSCI.20-11-04037.2000. J Neurosci. 2000. PMID: 10818139 Free PMC article.
Pharmacological characterization of senktide-induced tail whips.
Nordquist RE, Ballard TM, Algeyer B, Pauly-Evers M, Ozmen L, Spooren W. Nordquist RE, et al. Among authors: pauly evers m. Neuropharmacology. 2010 Jan;58(1):259-67. doi: 10.1016/j.neuropharm.2009.04.018. Epub 2009 Jun 21. Neuropharmacology. 2010. PMID: 19540857
Cognitive performance in neurokinin 3 receptor knockout mice.
Nordquist RE, Delenclos M, Ballard TM, Savignac H, Pauly-Evers M, Ozmen L, Spooren W. Nordquist RE, et al. Among authors: pauly evers m. Psychopharmacology (Berl). 2008 Jun;198(2):211-20. doi: 10.1007/s00213-008-1119-6. Epub 2008 Mar 20. Psychopharmacology (Berl). 2008. PMID: 18351324
15 results